#Truvada

Insurers must cover Truvada now that the U.S. Preventive Services Task Force gives it a Grade A recommendation.

The study also projected that PrEP use among adult gay and bi men would result in considerable reductions of HIV among adolescents.

A qualitative study sought to better understand the stressors and structural factors tied to lower PrEP use in this group.

The proposal allows pharmacies to dispense a first-time 30-day supply of the HIV prevention pill without a script.

A quarter of study participants accounted for three-quarters of newly diagnosed cases of chlamydia, gonorrhea and syphilis.

In the form of direct quotes from the participants

At this year’s AIDSWatch, activists called out CDC director Robert Redfield for the health agency’s patent rights on Truvada for PrEP.

“And So It Happened” profiles people taking HIV treatment and PrEP.

Truvada and Descovy are both highly effective and generally safe options for HIV prevention.

A photo journal of the #PrEP4All activists at the House hearings on Gilead, PrEP, and Truvada pricing.

Gilead Sciences CEO defends high drug prices and claims the CDC does not own the patent to HIV prevention pill Truvada.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

Do not fall for Gilead’s vile marketing ploy.

The Truvada manufacturer’s agreement with the Trump Administration is “a tremendous step toward ending the epidemic.”

This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.

Researchers surveyed PrEP-prescribing physicians in Western New York.